Search PubMed⌕ Search

Biomedical subjects

Y Takezawa

Publications and source records attributed to Y Takezawa.

84 records · Page 5Linked to original sources
PubMed1977

Difference of hepatic circulation between alcoholic and non-alcoholic hepatic cirrhosis.

Comparisons were made of hepatic circulation between alcoholic and non-alcoholic cirrhosis. The wedged hepatic venous pressure and per cent intrahepatic shunt measured by the method of continuous infusion of D-galactose-1-14C were similarly markedly increased. On the other hand, the wedged hepatic venography showed the main portal trunk and extrahepatic collaterals, namely, the tendency of reverse or stagnant portal flow, more frequently in alcoholic cirrhosis than in non-alcoholic cirrhosis. The nodules shown by slow low-pressure hepatic sinusoidography were larger in non-alcoholic cirrhosis than in alcoholic cirrhosis.

Blood Pressure↗
PubMed1977

Alcoholic hepatitis with and without alcoholic hyaline.

Sixteen cases of alcoholic hepatitis with alcoholic hyaline (Group I) and 13 cases without alcoholic hyaline (Group II) have been collected since 1970. These were most frequently found in the fifth decade in both groups. One female was found in Group I. Cases of about two-thirds of both groups were comsumers of 110 g or more of alcohol per day. No significant differences except fever and erythrocyte sedimentation rate were found in clinical and laboratory changes between both groups. Fatty change in liver biopsy specimens were more frequently seen in Group I than in Group II. The wedged hepatic venous pressure was markedly elevated in alcoholic hepatitis with cirrhosis and moderately elevated in alcoholic hepatitis without cirrhosis. Wedged hepatic venography showed the main portal trunk and extrahepatic collaterals, namely, reversal of the portal flow or such tendency in 2 out of 5 patients of Group I.

Adult↗
PubMed1976

Phytohemagglutinin-induced lymphocyte transformation in liver diseases and in asymptomatic HBsAg carriers.

Phytohemagglutin (PHA)-induced lymphocyte transformation was impaired in acute viral hepatitis. It was significantly correlated with grades of liver cell damage as shown by prothrombin time, GOT, or GPT. It was also lower in drug-induced hepatitis and in prolonged hepatitis than in controls. Of asymptomatic HBsAg carriers, only those with minimal hepatic change showed lower values in stimulation index as well as incorporated radioactivity.

Carrier State↗
PubMed1976

Measurement of intrahepatic shunted blood flow by ethanol-1-14C method as compared with D-galactose-1-14C method.

Ethanol-1-14C method for the measurement of intrahepatic shunted blood flow was compared with the method of continuous infusion of D-galactose-1-14C. In controls, in chronic hepatitis, and in hepatic cirrhosis, per cent intrahepatic shunt measured by the ethanol-1-14C- method was about a half or one-third of that measured by the D-galactose-1-14C method. Study of radioactivity-dye concentration ratio of the blood sampled from the inferior vena cava showed that per cent intrahepatic shunt was underestimated by the ethanol-1-14C method because of permeability of ethanol-1-14C through the capillaries. In patients with hepatic carcinoma, in whom the carcinomatous tissue was supplied mainly by the hepatic artery, there was no significant difference in per cent intrahepatic shunt between both methods.

Ethanol↗
PubMedDate not supplied

[PSA doubling time in prostate cancer relapsed after endocrine therapy].

PURPOSE: The PSA level of prostate cancer patients generally declines after endocrine therapy, but elevates when the cancer relapses in most cases. However, the rate of elevation differs with the case. We investigated the PSA doubling time (PSA-DT) of the prostate cancer patients whose PSA declined after endocrine therapy and later re-elevated, and investigated the relationship with other parameters. PATIENTS AND METHODS: We investigated 55 prostate cancer patients who underwent endocrine therapy between 1991 and 1998. Their PSA re-elevated continuously after their PSA fell below 10 ng/ml after the endocrine therapy as the first line treatment. First, the correlation coefficients with time and PSA were calculated in order to decide whether their PSA elevation was exponential or linear. PSA-DT was calculated thereafter, and compared with the clinical stage, pathological differentiation, clinical relapse style, time from the beginning of the therapy to PSA relapse, pre-treatment PSA value, and prognosis. The relationship between PSA-DT and each clinical parameter was tested using the Kruskal-Wallis test. Differences in survival rates and PSA-DT were calculated using the log-rank test. RESULTS: PSA elevated exponentially after cancer relapsed. PSA-DT in all cases ranged from 0.5 to 26.3 months, with an average of 4.4 +/- 4.8 (S.D.) months and the median was 2.5 months. PSA-DT was significantly (p < 0.01) short when the pre-treatment clinical stage was high, the time from the beginning of the therapy to PSA relapse was short, or the pre-treatment PSA value was high. PSA-DT tended to be short when the pre-treatment pathological differentiation was low, but not significantly. PSA-DT tended to be short when the cancer relapsed as distant metastasis rather than regional relapse, but not significantly. Prognosis from the initial treatment and PSA relapse was significantly poor when the PSA-DT was short. CONCLUSIONS: PSA elevated exponentially in the relapsed prostate cancer patients after the endocrine therapy. PSA-DT was distributed in a very wide range, and this value was considered to reflect the malignant potential and prognosis of the cancer. PSA-DT may be useful for determining the strategy after relapse.

Aged↗